Loading...
Time from randomization to any evidence of tumour recurrence (invasive and non-invasive) in the treated breast.
Cosmesis will be assessed by the patient using the Breast Cosmesis Questionnaire which incorporates the Modified EORTC Breast Cosmetic Rating System and the UK Patient Reported Outcomes Questions following BCS.
Time from randomization to evidence of metastasis involving distant sites (e.g. bone, liver, lung, or brain).
Time from randomization to local recurrence, regional or distant recurrence, contralateral breast cancer, other second cancer, or death.
Time from randomization to death of any cause.
Acute (2 weeks and up to 3 months after completing RT) and late toxicity (beyond the 3 months after completing RT) will be assessed by clinical centre personnel using the NCI CTCAE version 5.0.
A nurse/Clinical Research Associate (CRA) assessment of cosmesis using the EORTC Breast Cosmetic Rating System. Nurses and CRAs will be training in assessing cosmesis using training slides and guide previously developed for other trials.
Cosmesis will be assessed by the patient using the Breast Cosmesis Questionnaire which incorporates the Modified EORTC Breast Cosmetic Rating System13,27,42 and the UK Patient Reported Outcomes Questions following BCS.
Patients will complete the EORTC Breast Cancer Quality of life questionnaire